Comparative Pharmacology
Head-to-head clinical analysis: CERADON versus KENALOG H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERADON versus KENALOG H.
CERADON vs KENALOG-H
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
Triamcinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
2-40 mg (0.1-1 mL) intra-articular, intralesional, or soft tissue injection; intra-articular dose depends on joint size (large joint: 10-40 mg, medium joint: 5-25 mg, small joint: 2-10 mg); repeat every 2-3 weeks as needed.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 2-3 hours for triamcinolone acetonide. In the context of intra-articular or intralesional administration, the half-life at the site of action is prolonged due to slow release from the injection depot, providing sustained local effects.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours.
Renal excretion of metabolites (primarily conjugated and unconjugated) accounts for approximately 80-90% of an administered dose, with less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder, about 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid